Nicholas Restifo
About Nicholas Restifo
Nicholas Restifo is a Principal Investigator at the National Institutes of Health, where he has worked since 1989. He also serves as Executive Vice President for Research at Lyell Immunopharma and has an extensive academic background in medicine and cancer research.
Work at National Institutes of Health
Nicholas Restifo has served as a Principal Investigator at the National Institutes of Health (NIH) for 35 years, starting in 1989. His role involves leading research initiatives and contributing to advancements in the field of cancer immunology. The NIH is a key institution for biomedical research, and Restifo's work focuses on understanding the immune response to cancer, which is critical for developing effective therapies.
Education and Expertise
Restifo's educational background includes a Bachelor’s degree from The Johns Hopkins University, completed from 1979 to 1983. He then pursued a Doctor of Medicine degree at New York University School of Medicine, where he studied from 1983 to 1987. His extensive training in medicine and cancer research has equipped him with the expertise necessary for his current research endeavors.
Previous Experience at Memorial Sloan Kettering Cancer Center
Before joining the NIH, Nicholas Restifo worked as a Postdoctoral Fellow at Memorial Sloan Kettering Cancer Center in New York City from 1988 to 1989. This role provided him with valuable experience in cancer research, further shaping his career in immunology and paving the way for his future contributions at the NIH.
Current Role at Lyell Immunopharma
In addition to his work at the NIH, Restifo has been serving as the Executive Vice President for Research at Lyell Immunopharma since 2019. This position allows him to apply his research expertise in a corporate setting, focusing on innovative approaches to cancer treatment through immunotherapy.
Long-Term Commitment to Cancer Research
Nicholas Restifo has dedicated over three decades to cancer research, primarily at the NIH. His long-term commitment reflects his focus on advancing the understanding of cancer immunology and developing new therapeutic strategies. His work has implications for improving patient outcomes in cancer treatment.